Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York, NY 10021, USA.
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Eur Heart J Qual Care Clin Outcomes. 2024 Jun 20;10(4):345-356. doi: 10.1093/ehjqcco/qcad057.
Most cancer patients require surgery for diagnosis and treatment. This study evaluated whether cancer is a risk factor for perioperative arterial ischaemic events.
The primary cohort included patients registered in the National Surgical Quality Improvement Program (NSQIP) between 2006 and 2016. The secondary cohort included Healthcare Cost and Utilization Project (HCUP) claims data from 11 US states between 2016 and 2018. Study populations comprised patients who underwent inpatient (NSQIP, HCUP) or outpatient (NSQIP) surgery. Study exposures were disseminated cancer (NSQIP) and all cancers (HCUP). The primary outcome was a perioperative arterial ischaemic event, defined as myocardial infarction or stroke diagnosed within 30 days after surgery.
Among 5 609 675 NSQIP surgeries, 2.2% involved patients with disseminated cancer. The perioperative arterial ischaemic event rate was 0.96% among patients with disseminated cancer vs. 0.48% among patients without (hazard ratio [HR], 2.01; 95% confidence interval [CI], 1.90-2.13). In Cox analyses adjusting for demographics, functional status, comorbidities, surgical specialty, anesthesia type, and clinical factors, disseminated cancer remained associated with higher risk of perioperative arterial ischaemic events (HR, 1.37; 95% CI, 1.28-1.46). Among 1 341 658 surgical patients in the HCUP cohort, 11.8% had a diagnosis of cancer. A perioperative arterial ischaemic event was diagnosed in 0.74% of patients with cancer vs. 0.54% of patients without cancer (HR, 1.35; 95% CI, 1.27-1.43). In Cox analyses adjusted for demographics, insurance, comorbidities, and surgery type, cancer remained associated with higher risk of perioperative arterial ischaemic events (HR, 1.31; 95% CI, 1.21-1.42).
Cancer is an independent risk factor for perioperative arterial ischaemic events.
大多数癌症患者需要手术进行诊断和治疗。本研究评估了癌症是否是围手术期动脉缺血事件的危险因素。
主要队列纳入了 2006 年至 2016 年期间在美国国家外科质量改进计划(NSQIP)注册的患者。次要队列纳入了 2016 年至 2018 年期间来自美国 11 个州的医疗保健成本和利用项目(HCUP)的索赔数据。研究人群包括接受住院(NSQIP,HCUP)或门诊(NSQIP)手术的患者。研究暴露包括散发癌症(NSQIP)和所有癌症(HCUP)。主要结局是围手术期动脉缺血事件,定义为术后 30 天内诊断出的心肌梗死或中风。
在 5609675 例 NSQIP 手术中,有 2.2%的患者患有散发癌症。患有散发癌症的患者围手术期动脉缺血事件发生率为 0.96%,而无癌症的患者为 0.48%(风险比[HR],2.01;95%置信区间[CI],1.90-2.13)。在调整人口统计学、功能状态、合并症、手术专业、麻醉类型和临床因素的 Cox 分析中,散发癌症与围手术期动脉缺血事件的风险增加相关(HR,1.37;95%CI,1.28-1.46)。在 HCUP 队列中,1341658 例手术患者中,11.8%的患者被诊断为癌症。患有癌症的患者中有 0.74%诊断出围手术期动脉缺血事件,而无癌症的患者为 0.54%(HR,1.35;95%CI,1.27-1.43)。在调整人口统计学、保险、合并症和手术类型的 Cox 分析中,癌症与围手术期动脉缺血事件的风险增加相关(HR,1.31;95%CI,1.21-1.42)。
癌症是围手术期动脉缺血事件的独立危险因素。